A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Two Dose Levels of EMA401 in Patients With Postherpetic Neuralgia

Trial Profile

A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Two Dose Levels of EMA401 in Patients With Postherpetic Neuralgia

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2015

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Spinifex Pharmaceuticals
  • Most Recent Events

    • 25 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov
    • 29 Jun 2015 Novartis plans to initiate this study after acquisition of Spinifex Pharmaceuticals in H2 2015.
    • 23 Apr 2015 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top